Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% IN PLASTIC CONTAINER vs DEXTROSE 7.7% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides a source of calories and fluid for parenteral nutrition. It increases blood glucose levels and is metabolized to carbon dioxide and water, providing energy. It also serves as a source of water for hydration.
Dextrose is a simple sugar that provides a source of calories and fluid for intravenous administration. It increases blood glucose levels, enhancing cellular metabolism and energy production via the glycolytic pathway and subsequent oxidative phosphorylation.
Intravenous infusion for parenteral nutrition when oral intake is inadequate,Treatment of hypoglycemia,Fluid resuscitation in dehydrated patients,As a vehicle for intravenous drug delivery
FDA-approved: Peripheral parenteral nutrition supplementation in patients who require caloric intake but cannot take adequate oral nutrition,Off-label: Treatment of hypoglycemia, as a component of total parenteral nutrition
Intravenous infusion: 500-1000 m L as needed based on fluid and caloric requirements. Typical rate: 100-200 m L/hour for maintenance. Maximum infusion rate: 0.5-0.8 g/kg/hour.
Intravenous infusion. Typical adult dose is 500-1000 m L of 7.7% dextrose solution infused at a rate of 100-200 m L/hour, titrated to clinical response and serum glucose levels.
Intravenous: 1.5-2.5 hours for glucose clearance; prolonged in renal impairment or diabetes mellitus
30-60 minutes for blood glucose to return to baseline after infusion cessation; clinical context: rapid metabolism via glycolysis.
Dextrose is metabolized via glycolysis and subsequently enters the citric acid cycle (Krebs cycle) to produce ATP. It is also stored as glycogen in the liver and muscles.
Dextrose undergoes glycolysis and enters the Krebs cycle to produce ATP. It is metabolized via the Embden-Meyerhof pathway and the pentose phosphate pathway. Insulin facilitates cellular uptake.
Renal: negligible as unchanged drug; metabolized to water and carbon dioxide, excreted via lungs (>90%) and urine (glucose normally <0.1%)
Renal: 100% as CO2 and water; no unchanged dextrose excreted in urine under normal conditions.
Negligible (<5%); not bound to plasma proteins
None (0%); dextrose does not bind to plasma proteins.
Approximately 0.15-0.25 L/kg; approximates extracellular fluid volume; expands in hyperglycemia or fluid overload
0.15-0.25 L/kg; approximates extracellular fluid volume.
Intravenous: 100%; oral: not applicable (dextrose administered parenterally)
Oral: 100% (dextrose is completely absorbed).
No specific GFR-based dose adjustment; monitor serum glucose and electrolytes, especially in severe renal impairment (GFR <15 m L/min) due to risk of fluid overload and hyperglycemia.
No specific dose adjustment for GFR; however, monitor fluid balance and serum glucose in patients with renal impairment due to risk of fluid overload and hyperglycemia.
No specific Child-Pugh based adjustment; caution in severe hepatic impairment due to impaired gluconeogenesis, risk of hypoglycemia.
No specific dose adjustment for Child-Pugh class; monitor serum glucose closely in patients with hepatic impairment due to altered glucose metabolism.
Neonates: 6-12 mg/kg/min as continuous IV infusion. Infants/children: 2-6 mg/kg/min for maintenance. Adjust rate based on glucose needs.
Intravenous infusion at a dose of 5-10 m L/kg of 7.7% dextrose solution, infused at a rate not to exceed 0.5-1 g/kg/hour of dextrose, with careful monitoring of serum glucose.
Use with caution due to decreased renal function and higher risk of hyperglycemia and volume overload. Start at lower rates (50-100 m L/hour) and titrate based on response.
Use with caution; consider lower infusion rates and volumes due to decreased renal function and increased risk of fluid overload and hyperglycemia. Monitor serum glucose and electrolytes frequently.
None. Dextrose 5% in plastic container does not have an FDA black box warning.
No black box warning.
Risk of hyperglycemia in patients with diabetes mellitus or glucose intolerance,Monitor serum glucose levels closely in patients with impaired glucose tolerance,Avoid in patients with intracranial or intraspinal hemorrhage,Use with caution in patients with renal impairment due to risk of fluid overload,Do not administer if solution is cloudy or contains particles
Use with caution in patients with diabetes mellitus or glucose intolerance; may cause hyperglycemia,Monitor serum glucose levels during administration,Risk of fluid overload in patients with renal or cardiac impairment,Avoid extravasation; can cause tissue necrosis,High concentrations may cause hyperosmolality and osmotic diuresis
Hypersensitivity to dextrose or any components,Intracranial or intraspinal hemorrhage,Severe dehydration with hypernatremia,Diabetic coma with hyperglycemia
Hyperglycemia or diabetes mellitus when uncontrolled,Intracranial or intraspinal hemorrhage (contraindicated for certain dextrose-containing solutions),Known allergy to dextrose or corn products,Severe dehydration with anuria,Delirium tremens in patients with known ethanol intolerance (for high-concentration solutions)
No significant food interactions; monitor dietary carbohydrate intake if hyperglycemia occurs.
No specific food interactions. However, because this is a parenteral solution, oral intake may be restricted per clinical condition. Monitor blood glucose levels closely if oral intake is resumed.
Dextrose is an essential nutrient; no teratogenic risk at therapeutic doses. IV administration in pregnancy is safe; risk of maternal hyperglycemia may increase fetal macrosomia and neonatal hypoglycemia. No trimester-specific fetal malformation risk.
Dextrose is a physiological nutrient; at standard infusion rates, no teratogenic effects are expected. However, hyperglycemia from excessive infusion may increase the risk of fetal macrosomia, neonatal hypoglycemia, and congenital anomalies (first trimester). Avoid maternal hyperglycemia.
Dextrose is endogenous and safe during breastfeeding; no known adverse effects. M/P ratio not applicable as it is a physiologic sugar; no special precautions needed.
Dextrose is a normal blood constituent; no significant excretion into breast milk. M/P ratio not applicable. Safe during breastfeeding when used at recommended doses; monitor for maternal hyperglycemia.
No dose adjustment required for pregnancy. Monitor for fluid overload and hyperglycemia; consider decreased osmotic threshold. Maintain euglycemia; adjust infusion rate if gestational diabetes present.
No specific dose adjustment required for dextrose itself. However, pregnant patients may have altered glucose metabolism; adjust infusion rate to avoid hyperglycemia or hypoglycemia. Monitor for gestational diabetes.
Dextrose 5% in water is isotonic but becomes hypotonic after dextrose metabolism; monitor for hyperglycemia in stressed patients; avoid in patients with intracranial hemorrhage solutions; use with caution in renal impairment due to risk of fluid overload.
Dextrose 7.7% is a hypertonic solution (approx. 770 m Osm/L) that must be administered via a central venous line to avoid phlebitis. It is commonly used as a component of parenteral nutrition or for treatment of hypoglycemia. Monitor serum glucose closely; rapid infusion can cause hyperglycemia and osmotic diuresis. Do not administer if solution is cloudy or contains precipitate.
Your IV bag contains sugar water to provide calories and hydration.,Tell your nurse if you feel increased thirst, frequent urination, or headache.,This solution may raise blood sugar, especially if you have diabetes.
This solution contains sugar (dextrose) and will be given through a central intravenous line.,Report any signs of infection at the catheter site, such as redness, swelling, or pain.,Notify your healthcare provider if you experience headaches, confusion, or frequent urination, which could indicate high blood sugar.,Do not adjust the infusion rate; it is precisely controlled to avoid complications.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% IN PLASTIC CONTAINER vs DEXTROSE 7.7% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Fluid that works by Dextrose is a monosaccharide that provides a source of calories and fluid for parenteral nutrition. It increases blood glucose levels and is metabolized to carbon dioxide and water, providing energy. It also serves as a source of water for hydration.. DEXTROSE 7.7% IN PLASTIC CONTAINER is a Intravenous Fluid that works by Dextrose is a simple sugar that provides a source of calories and fluid for intravenous administration. It increases blood glucose levels, enhancing cellular metabolism and energy production via the glycolytic pathway and subsequent oxidative phosphorylation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% IN PLASTIC CONTAINER and DEXTROSE 7.7% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Intravenous Fluid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion: 500-1000 m L as needed based on fluid and caloric requirements. Typical rate: 100-200 m L/hour for maintenance. Maximum infusion rate: 0.5-0.8 g/kg/hour.. The standard adult dose of DEXTROSE 7.7% IN PLASTIC CONTAINER is: Intravenous infusion. Typical adult dose is 500-1000 m L of 7.7% dextrose solution infused at a rate of 100-200 m L/hour, titrated to clinical response and serum glucose levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXTROSE 5% IN PLASTIC CONTAINER and DEXTROSE 7.7% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Dextrose is an essential nutrient; no teratogenic risk at therapeutic doses. IV administration in pregnancy is safe; risk of maternal hyperglycemia may increase fetal macrosomia an. DEXTROSE 7.7% IN PLASTIC CONTAINER is classified as Category C. Dextrose is a physiological nutrient; at standard infusion rates, no teratogenic effects are expected. However, hyperglycemia from excessive infusion may increase the risk of fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.